Literature DB >> 19925426

Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development.

P Anthony Akkari1, Thomas W Swanson, Donna G Crenshaw, Iris Grossman, Scott Sundseth, Daniel K Burns, Allen D Roses.   

Abstract

There has been a decline in the number of new drugs registered over the past decade and regulatory concerns for safety as well as payer concerns for efficacy have focused attention on stratified medicine. Integration of pharmacogenetics into the drug development pipeline will contribute to the development of new stratified drugs. We describe here the concept of pipeline pharmacogenetics and its application throughout the phases of drug discovery. Pipeline pharmacogenetics enables the evaluation of the genetic contribution to safety potentially lowering barriers to registration as well as providing rationale for efficacy and enabling co-development of genetic in vitro diagnostics.

Mesh:

Year:  2009        PMID: 19925426     DOI: 10.2174/138161209789649538

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Alzheimer's disease: diagnostics, prognostics and the road to prevention.

Authors:  Iris Grossman; Michael W Lutz; Donna G Crenshaw; Ann M Saunders; Daniel K Burns; Allen D Roses
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

2.  Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics.

Authors:  Iris Grossman; Ariel Miller
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.